Sandbox2: Difference between revisions
No edit summary |
|||
Line 10: | Line 10: | ||
[[WPW]] is a congenic disease | [[WPW]] is a congenic disease | ||
== | ==Diagnosis== | ||
Shown below is an algorithm summarizing the initial aproach to [[Wolff-Parkinson-White syndrome]] according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary | url = http://circ.ahajournals.org/content/108/15/1871 | publisher = | date = | accessdate = 15 August 2013 }}</ref> | Shown below is an algorithm summarizing the initial aproach to [[Wolff-Parkinson-White syndrome]] according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary | url = http://circ.ahajournals.org/content/108/15/1871 | publisher = | date = | accessdate = 15 August 2013 }}</ref> | ||
'''AVRT''': [[AV reentrant tachycardia]] | '''AVRT''': [[AV reentrant tachycardia]] | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | A01 | | A01=<div style="float: left; text-align: left; width: 27em; padding:1em;"> '''Characterize the symptoms:'''<br> | {{familytree | | | | | | | | | | | | | A01 | | A01=<div style="float: left; text-align: left; width: 27em; padding:1em;"> '''Characterize the symptoms:'''<br> | ||
Line 48: | Line 48: | ||
❑ Treat reversible causes if identified | ❑ Treat reversible causes if identified | ||
</div>}} | </div>}} | ||
{{familytree | | | | | | | | | | | | | |! | {{familytree | | | | | | | | | | | | | |!| | | |}} | ||
{{familytree | | | | | | | | | |,|-|-|-|^|-|-|-|. | {{familytree | | | | | | | | | |,|-|-|-|^|-|-|-|.| | | |}} | ||
{{familytree | | | | | | | | | D01 | | | | | | D02 | | | | D01 | {{familytree | | | | | | | | | D01 | | | | | | D02 | | | | D01= <div style="float: left; text-align: left; width: 24em; padding:1em;"> '''Orthodromic AVRT''' '''<br> | ||
The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of [[WPW]]''' | |||
The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of [[WPW]] | |||
❑ Narrow QRS complexes <br> | ❑ Narrow QRS complexes <br> | ||
Line 62: | Line 57: | ||
❑ Short PR interval less than one half of the tachycardia RR interval | ❑ Short PR interval less than one half of the tachycardia RR interval | ||
</div>| | </div>| | ||
D02= <div style="float: left; text-align: left; width: 24em; padding:1em;"> '''Antidromic AVRT''' <br> | |||
The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of [[WPW]] | The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of [[WPW]] | ||
Line 69: | Line 64: | ||
❑ Short PR interval more than one half of the tachycardia RR interval | ❑ Short PR interval more than one half of the tachycardia RR interval | ||
</div> }} | </div> }} | ||
{{familytree/end}} | |||
==Managment== | |||
===Initial Management=== | |||
Shown below is an algorithm summarizing the initial aproach to [[Wolff-Parkinson-White syndrome]] according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary | url = http://circ.ahajournals.org/content/108/15/1871 | publisher = | date = | accessdate = 15 August 2013 }}</ref> | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | | | | | A01 | | | A01= <div style="float: left; text-align: left; width: 24em; padding:1em;"> | |||
❑ Determine blood pressure <br> | |||
❑ Determine heart rate <br> | |||
</div>}} | |||
{{familytree | | | | | | | | | | | | | |!| | | | | | || | |}} | |||
{{familytree | | | | | | | | | |,|-|-|-|^|-|-|-|.| | | | |}} | |||
{{familytree | | | | | | | | | D01 | | | | | | D02 | | | | D01= '''Stable patient'''| D02= '''Unstable patient'''}} | |||
{{familytree | | | | | | | | | |!| | | | | | | |!| | | | }} | |||
{{familytree | | | | | | | | | E01 | | | | | | E02 | | | | E01=❑ Assess the [[ECG]] | E02=❑ Urgent electrical [[cardioversion]]}} | |||
{{familytree | | | | | | | | | |!| | | | | | | }} | |||
{{familytree | | | | | |,|-|-|-|^|-|-|-|.| | | | | }} | |||
{{familytree | | | | | F01 | | | | | | F02 | | | | | F01= '''Orthodromic AVRT'''| F02= '''Antidromic AVRT'''}} | |||
{{familytree | | | | | |!| | | | | | | |!| | | | | |}} | {{familytree | | | | | |!| | | | | | | |!| | | | | |}} | ||
{{familytree | | | | | G01 | | | | | | G02 | | | | G01=<div style="float: left; text-align: left;"> '''Treatment.'''<ref name="Mehta-1988">{{Cite journal | last1 = Mehta | first1 = D. | last2 = Wafa | first2 = S. | last3 = Ward | first3 = DE. | last4 = Camm | first4 = AJ. | title = Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. | journal = Lancet | volume = 1 | issue = 8596 | pages = 1181-5 | month = May | year = 1988 | doi = | PMID = 2897005 }}</ref><ref name="Jackman-1988">{{Cite journal | last1 = Jackman | first1 = WM. | last2 = Friday | first2 = KJ. | last3 = Fitzgerald | first3 = DM. | last4 = Yeung-Lai-Wah | first4 = JA. | last5 = Lazzara | first5 = R. | title = Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. | journal = Am J Cardiol | volume = 62 | issue = 19 | pages = 8L-19L | month = Dec | year = 1988 | doi = | PMID = 3059792 }}</ref><ref name="Sung-1980">{{Cite journal | last1 = Sung | first1 = RJ. | last2 = Elser | first2 = B. | last3 = McAllister | first3 = RG. | title = Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. | journal = Ann Intern Med | volume = 93 | issue = 5 | pages = 682-9 | month = Nov | year = 1980 | doi = | PMID = 7212475 }}</ref><br> | {{familytree | | | | | G01 | | | | | | G02 | | | | G01=<div style="float: left; text-align: left;"> '''Treatment.'''<ref name="Mehta-1988">{{Cite journal | last1 = Mehta | first1 = D. | last2 = Wafa | first2 = S. | last3 = Ward | first3 = DE. | last4 = Camm | first4 = AJ. | title = Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. | journal = Lancet | volume = 1 | issue = 8596 | pages = 1181-5 | month = May | year = 1988 | doi = | PMID = 2897005 }}</ref><ref name="Jackman-1988">{{Cite journal | last1 = Jackman | first1 = WM. | last2 = Friday | first2 = KJ. | last3 = Fitzgerald | first3 = DM. | last4 = Yeung-Lai-Wah | first4 = JA. | last5 = Lazzara | first5 = R. | title = Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. | journal = Am J Cardiol | volume = 62 | issue = 19 | pages = 8L-19L | month = Dec | year = 1988 | doi = | PMID = 3059792 }}</ref><ref name="Sung-1980">{{Cite journal | last1 = Sung | first1 = RJ. | last2 = Elser | first2 = B. | last3 = McAllister | first3 = RG. | title = Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. | journal = Ann Intern Med | volume = 93 | issue = 5 | pages = 682-9 | month = Nov | year = 1980 | doi = | PMID = 7212475 }}</ref><br> | ||
Line 82: | Line 96: | ||
{{familytree/end}} | {{familytree/end}} | ||
=== | ===Wolff-Parkinson-White syndrome with Atrial fibrillation=== | ||
Shown below is an algorithm summarizing the managment of [[Wolff-Parkinson-White syndrome]]with [[Atrial fibrillation]] according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.<ref name="Fuster-2006">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Le Heuzey | first8 = JY. | last9 = Kay | first9 = GN. | title = ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal = Circulation | volume = 114 | issue = 7 | pages = e257-354 | month = Aug | year = 2006 | doi = 10.1161/CIRCULATIONAHA.106.177292 | PMID = 16908781 }}</ref> | Shown below is an algorithm summarizing the managment of [[Wolff-Parkinson-White syndrome]]with [[Atrial fibrillation]] according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.<ref name="Fuster-2006">{{Cite journal | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Le Heuzey | first8 = JY. | last9 = Kay | first9 = GN. | title = ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. | journal = Circulation | volume = 114 | issue = 7 | pages = e257-354 | month = Aug | year = 2006 | doi = 10.1161/CIRCULATIONAHA.106.177292 | PMID = 16908781 }}</ref> | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | A01 | | | | | | | | | A01=<div style="float: left; text-align: left; width: 27em; padding:1em;"><br> | {{familytree | | | | | | | | | | A01 | | | | | | | | | A01=<div style="float: left; text-align: left; width: 27em; padding:1em;"><br> | ||
❑ Control ventricular response<br> | ❑ Control ventricular response<br> |
Revision as of 14:26, 19 March 2014
|
Overview
Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent. The diagnosis is made when a patient with pre-existing WPW patern in the ECG developes an arrythmia which involves an accesory pathway. The treatment is focused on recovering sinus rythm. Atrial Fibrillation in a patient with WPW is lifethretening and should be managed urgently.
Causes
Life Threatening Causes
Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.
Common Causes
WPW is a congenic disease
Diagnosis
Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
AVRT: AV reentrant tachycardia
Characterize the symptoms:
Characterize the timing of the symptoms: | |||||||||||||||||||||||||||||||||||||||||||
Identify possible triggers: | |||||||||||||||||||||||||||||||||||||||||||
❑ Examine the patient
❑ Order and monitor the ECG | |||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW ❑ Narrow QRS complexes | Antidromic AVRT The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW ❑ Wide QRS complexes | ||||||||||||||||||||||||||||||||||||||||||
Managment
Initial Management
Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]
❑ Determine blood pressure | |||||||||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the ECG | ❑ Urgent electrical cardioversion | ||||||||||||||||||||||||||||||||||||||||||||||
Orthodromic AVRT | Antidromic AVRT | ||||||||||||||||||||||||||||||||||||||||||||||
Treatment.[2][3][4] ❑ Use Valsalva maneuvers | Treatment. ❑ Administration of Procainamide, Flecainide or Ibutilide is the prefered treatment | ||||||||||||||||||||||||||||||||||||||||||||||
Wolff-Parkinson-White syndrome with Atrial fibrillation
Shown below is an algorithm summarizing the managment of Wolff-Parkinson-White syndromewith Atrial fibrillation according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.[5]
❑ Control ventricular response | |||||||||||||||||||||||||||||||||||||||||
Stable patient | Unstable patient | ||||||||||||||||||||||||||||||||||||||||
❑ Restore sinus rythm (class I, level of evidence C)
❑ Avoid AV blocking agents (class III, level of evidence B) | ❑ Urgent electric cardioversion (class I, level of evidence B) | ||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
- ↑ Mehta, D.; Wafa, S.; Ward, DE.; Camm, AJ. (1988). "Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia". Lancet. 1 (8596): 1181–5. PMID 2897005. Unknown parameter
|month=
ignored (help) - ↑ Jackman, WM.; Friday, KJ.; Fitzgerald, DM.; Yeung-Lai-Wah, JA.; Lazzara, R. (1988). "Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia". Am J Cardiol. 62 (19): 8L–19L. PMID 3059792. Unknown parameter
|month=
ignored (help) - ↑ Sung, RJ.; Elser, B.; McAllister, RG. (1980). "Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations". Ann Intern Med. 93 (5): 682–9. PMID 7212475. Unknown parameter
|month=
ignored (help) - ↑ Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Le Heuzey, JY.; Kay, GN. (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (7): e257–354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781. Unknown parameter
|month=
ignored (help)